Send a text

Think HIPAA is your biggest hurdle in pharma marketing? Think again. In this episode of KLF Deep Dive, Darshan Kulkarni reveals why focusing solely on HIPAA leaves a massive, unregulated gap in your compliance strategy. We break down the "layered system" of risk—from aggressive state privacy laws and medical privacy statutes to the DOJ’s massive 2025 Bulk Data Rule. Whether you’re running patient engagement campaigns or leveraging marketing automation, you’ll learn why the tools you use to scale might be the very tools that trigger a regulatory audit. Don't leave your firm's reputation to a "narrow slice" of engagement.

Support the show

www.kulkarnilawfirm.com

Send a text

The "handshake" era of cosmetic compliance is officially over. Under new authorities in Sections 605, 610, and 704, the FDA has moved from simple observation to an aggressive "access and copy" mandate. In this episode, Darshan Kulkarni breaks down the "SAHCOD" threat and explains why your internal communications, medical assessments, and even cross-contamination logs are now fair game for federal investigators. If you handle raw materials or shared manufacturing equipment, your entire catalog could be at risk of a forensic audit. Learn where the FDA's power ends—and where your defense begins.

Support the show

www.kulkarnilawfirm.com

Send a text

In clinical research, if it isn't documented, it never happened. Many site owners mistake a competent team for a compliant one—a mistake that leads to disastrous FDA inspections and lost sponsor contracts. In this KLF Deep Dive, Darshan Kulkarni reveals the specific training SOPs, log templates, and contract clauses required to protect your site. Learn how to bridge the gap between "doing the work" and "proving the work" so you can demonstrate a culture of readiness that sponsors trust.

Support the show

www.kulkarnilawfirm.com